Alan Wake 2 and Management developer Treatment has introduced its monetary outcomes for the third quarter of its fiscal yr, and issues are wanting a bit of rosier for the Finnish studio.
In Treatment’s monetary report, the studio says its income has jumped 128.6% over the identical interval from the earlier yr. Between July and September this yr, Treatment raked in €17.9 million in income, and its working revenue was €2.4 million, up from a €5.5 million loss in Q3 2023.
The studio additionally says that whereas Alan Wake 2 nonetheless is not worthwhile, the sport had recouped “most of its growth and advertising and marketing bills” by the top of the quarter, which implies that it might be worthwhile inside the subsequent couple of quarters.
In line with Treatment, full manufacturing on Management 2 is scheduled to begin in 2025, with the sequel at the moment progressing “nicely within the manufacturing readiness stage”. Most of the recreation’s “essential options” have been applied, Treatment says, and it is at the moment testing “workflows and pipelines” for full manufacturing.
Equally, the upcoming Max Payne remakes are “making regular progress”, and Treatment says it is “steadily reaching essential milestones” in growth on the initiatives.
For the remainder of 2024, Treatment expects its income to “improve from the earlier yr”, and it additionally expects its “working revenue to enhance”, so it appears like Treatment will possible have a greater time in 2024 than in 2023.
The report additionally appears forward to Treatment’s upcoming initiatives, together with the aforementioned Management 2 and the recently-revealed FBC: Firebreak, a multiplayer Management spinoff set to launch someday subsequent yr.
Whereas Treatment is teaming up with Annapurna (even amidst that firm’s current turmoil) for Management 2, the Finnish developer will probably be self-publishing the sport, as it should with FBC: Firebreak.
Here is hoping Treatment’s fortunes proceed to enhance within the coming months. Keep tuned for extra on all issues Treatment-related.
